Listar DMPSP - Artículos por financiación

Mostrando ítems 21-40 de 51

      Financiación
      The study was supported by research grants from the Spanish Health Research Fund ISCIII cofunded by FEDER funds -a way to build Europe (http://www.isciii.es/): PFN: FIS PI11/ 00871, BPG: FIS PI12/00150, PI17CIII/00034, GLA: PI14CIII/00050, JJJM: PI15/00914; Joint Action InfAct (European Commission): BPG: HPJA- 06-2017, PFN: HP-JA-06-2017. [1]
      The study was supported by the “Acción Transversal del Cáncer”, approved on the Spanish Ministry Council on the 11 October 2007, by the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), by the Instituto de Salud Carlos III grants, co-funded by FEDER funds -a way to build Europe- PI08/1770, PI09/0773, PI12/00715, PI09/1903,PI09/2078; PI09/1662; PI11/01403; PI12/00150; PI12/00488; PI15/00914; PI17CIII_00034;by the Fundación Marqués de Valdecilla grant API 10/09, by the Consejería de Salud of the Junta de Andalucía grant 2009-S0143, by the Conselleria de Sanitat of the Generalitat Valenciana grant AP061/10, by the Regional Government of the Basque Country, by the Fundación Caja de Ahorros de Asturias, by the University of Oviedo and by the Spanish Ministry of Economy and Competitiveness Juan de la Cierva de Incorporación grant IJCI-2014-20900. [1]
      This project is funded by Instituto de Salud Carlos III (ISCIII), the Spanish Government Official Agency for funding biomedical research - with competitive grants for the periods 2014–2016, 2015–2017, 2017–2019 and 2018–2020, through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund [grants: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728 PI13/01090 PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926] and the European Research Council [Advanced Research Grant 2014–2019; agreement #340918]. Additional grants: Acciones Especiales from ISCIIII, Consejería-Salud, Junta -Andalucía [PI0458/2013, PS0358/2016], Recercaixa-grant 2013 [2013ACUP00194], a SEMERGEN grant, International Nut & Dried Fruit Council – FESNAD No. 201302. Fundación Patrimonio Comunal Olivarero is providing the necessary amounts of olive oil. Nuts were initially and only partially provided by Pistachios Growers and Almond Board of California, for the pilot study. This research was also partially funded by EU-H2020 Grant (Eat2beNICE/H2020-SFS-2016–2; Ref 728018), PI14/00290 y PI17/1167(Co-funded by European Regional Development Fund, ERDF, a way to build Europe), PERIS (Generalitat de Catalunya, SLT006/17/00077), Grant PROMETEO/2017/017 (Generalitat Valenciana) and Grant FEA/SEA 2017 for Primary Care Research. We thank CERCA Programme/Generalitat de Catalunya for institutional support. ML-M is supported by a predoctoral Grant of the Ministerio de Educación, Cultura y Deporte (FPU15/02911). [1]
      This project is funded by the European Research Council (Advanced Research Grant 2013-2018; 340918) granted to MAM-G, the Spanish Ministry of Health - Instituto de Salud Carlos III (ISCIII) for the periods 2014-2016, 2015- 2017, 2017-2019 and 2018-2020, through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (four coordinated FIS grants lead by Jordi Salas-Salvadó and Josep Vidal, including the following projects: PI13/00673, PI13/ 00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728 PI13/01090 PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01374, PI14/01919, PI14/00853, PI16/00743 PI16/00501, PI17/ 000508), by a Recercaixa grant 2013 (2013ACUP00194), by a grant from the Consejería de Salud de la Junta de Andalucía (PI0458/2013), and a SEMERGEN grant. [1]
      This research was also supported in part by the STARS4ALL project funded by the H2020-ICT-2015-688135 program of the European Union, the ORISON project funded by the H2020-INFRASUPP-2015-2 program of the European Union, and through the resources of researchers and collaborators of the Cities at Night project. [1]
      This research was funded by Regional Ministry of Health of Andalusia/Consejería de Salud of the Junta de Andalucía (PI-0514-2016) and Instituto de Salud Carlos III-FEDER (PI15/00914). [1]
      This research was supported by the UK National Institute of Health Research, Research for Patient Benefit programme (RfPB PB-PG- 1013-32025). [1]
      This study was funded by grant number PI10/02018, Ministerio de Economía y Competitividad del Reino de España (Ministry of Economy and Competitiveness, Spain), Instituto de Salud Carlos III-FEDER. [1]
      This study was funded by the National Drug Plan from the Ministry of Health, Social Services and Equality of Spain (Codes: 2010|145 and 2013|034). [1]
      This study was funded by the National Drug Plan, Ministry of Health, Social Services and Equality of Spain (Codes: 2010|145 and 2013|034). [1]
      This study was funded by the National Drug Plan, Ministry of Health, Social Services and Equality of Spain (Codes: 2010|145 and 2013|034) and project PI16/01947. [1]
      This study was funded by the National Drug Plan, Ministry of Health, Social Services and Equality of Spain (Codes: 2010|145 and 2013|034). [1]
      This study was funded by the Spanish Ministry of Health (Carlos III Health Institute) through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (two coordinated FIS projects leaded by Jordi Salas-Salvadó and Josep Vidal, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728 PI13/01090 PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14- 00696, PI14/01206, PI14/01919, PI14/00853), the European Research Council (Advanced Research Grant 2013-2018; 340918) granted to MAMG, the Recercaixa grant 2013 (2013ACUP00194), the grant from the Consejería de Salud de la Junta de Andalucía (PI0458/2013), and the SEMERGEN grant. NRE has been beneficiary of a predoctoral FIAGAUR 2016 Grant from the Catalan Government; Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya. [1]
      This study was funded by: Scientific Foundation of the Spanish Association Against Cancer (Fundación Científica de la Asociación Española Contra el Cáncer (AECC) – EVP-1178/14), Spain's Health Research Fund (Fondo de Investigación Sanitaria – FIS 12/01416), the Spanish Ministry of Economy and Competitiveness (Carlos III Institute of Health; PI12/00488, PI12/00265, PI12/01270, PI12/ 00715, PI12/00150, PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI14/01219 and Río Hortega CM13/00232), the Catalan Government 2009SGR1489 & 2014SGR756-F, the Fundación Marqués de Valdecilla (API 10/09), the ICGC International Cancer Genome Consortium CLL, the Junta de Castilla y León (LE22A10-2), the Consejería de Salud of the Junta de Andalucía (PI-0571), the Conselleria de Sanitat of the Generalitat Valenciana (AP 061/10), the Recercaixa (2010ACUP 310), and the Regional Government of the Basque Country by European Commission grants FOOD-CT-2006-036224-HIWATE. [1]
      This study was supported by a grant from the Acción Estratégica en Salud plan for the High Resolution Project on Prognosis and Care of Cancer Patients (No. AC14/00036) awarded by the Spanish Ministry of Economy and Competitiveness and co-funded by the European Regional Development Fund (ERDF). [1]
      This work has been funded by the EC within the 7th Framework Programme under the COHEMI project - grant agreement no. FP7‐GA-26149 as well as the “Ramon y Cajal” fellowship program of the Spanish Ministry of Economy and Competitiveness (MINECO). [1]
      This work has been funded by the Precompetitive Research Projects for Young Researchers 2017—Modality B under grant PPJI_B-05 of the University of Granada (Spain). [1]
      This work was funded as part of a research agreement between the Ministerio de Agricultura, Alimentación y Medioambiente, Spain and the Instituto de Salud Carlos III, Madrid , Spain (Project N_ SEG 1251/ 07, 1210/10 and 1321/15). [1]
      This work was partially funded by the public grants from the Catalan Government (2014SGR756, 2017SGR1085, 2017SGR733, SLT006/17/76), and European Regional Development Fund-ERDF, by the “Accion Transversal del Cancer”, approved on the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos IIIFEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773-Cantabria, PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/ 01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/ 01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/ 00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/ 00914, PI15/01032, PI11/01810, PI14/01219, PI11/02213, PIE16/ 00049, PI17/01179), by the Fundación Marqués de Valdecilla (API 10/ 09), by the Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036), by the Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI- 0306-2011, salud201200057018tra), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government-Agency for Management of University and Research Grants (AGAUR) grants 2014SGR647 and 2014SGR850. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. [1]
      This work was partially funded by the “Accion Transversal del Cancer”, approved by the Spanish Ministry Council on the 11th October 2007; The Instituto de Salud Carlos III-FEDER [PI08/1770, PI08/0533, PI08/1359, PI09/ 00773-Cantabria, PI09/01286-León, PI09/01903-Valencia, PI09/02078-Huelva, PI09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032]; The Fundación Marqués de Valdecilla [API 10/09]; The ICGC International Cancer Genome Consortium CLL (The ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)); The Junta de Castilla y León [LE22A10–2]; The Consejería de Salud of the Junta de Andalucía [2009-S0143]; The Conselleria de Sanitat of the Generalitat Valenciana [AP_061/10]; The Recercaixa [2010ACUP 00310]; The Regional Government of the Basque Country; The Consejería de Sanidad de la Región de Murcia; The European Commission [grants FOOD-CT-2006-036224-HIWATE]; The Spanish Association Against Cancer (AECC) Scientific Foundation; The Catalan Government DURSI [grant 2014SGR647]; The Fundación Caja de Ahorros de Asturias; and the University of Oviedo. [1]